Skip to main content
SpringerLink
Log in

Dermatomyositis after interferon alpha treatment

  • Case Report
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

An association between auto-immune disorders and interferon (IFN) has been reported. High levels of natural IFNα are present in the blood of patients with auto-immune disease and correlate with disease activity. In addition, IFNα treatment of humans has resulted in multiple reports of associatied auto-immune phenomena. We describe a patient who underwent resection of regionally metastatic melanoma, was given adjuvant high-dose IFNα2b, and subsequently developed dermatomyositis. To the author's knowledge this is the first report of dermatomyositis in association with IFNα treatment. We review the literature reporting associations between IFNα and auto-immune disease and discuss possible mechanisms by which IFNα may contribute to the development of auto-immune disease. High dose IFNα2b is more commonly prescribed since it was approved as an adjuvant treatment for patients with surgically resected high-risk melanoma. The potential for cases of IFN-associated autoimmune disease is therefore a clinical concern. Standard side effects of high-dose IFN therapy resemble symptoms of auto-immune diseases, which may make prompt diagnosis difficult. Therefore, it is important that auto-immune diseases such as dermatomyositis are recognized as potential side effects of treatment with high-dose IFNα.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Dalakas M. Polymyositis, Dermatomyositis and inclusion body motositis.New Engl J Med 1991;325: 1487–1498.

    Article  CAS  PubMed  Google Scholar 

  2. Banker BQ, Engel AG. The polymyositis and dermatomyositis syndromes. In: Engel AG, Banker BQ (eds).Myology. New York: McGraw-Hill, 1986, pp 1385–1422.

    Google Scholar 

  3. Carpenter S. Resin histology and electron microscopy in inflammatory myopathy. In: Dalakas MC (ed).Polymyositis and Dermatomyositis Boston: Butterworths, 1988, 195–215.

    Chapter  Google Scholar 

  4. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells.Ann. Neurol 1984;16: 193–208.

    Article  CAS  PubMed  Google Scholar 

  5. Engel AG, Arahata K. Mononuclear cells in myopathies: quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases and implications for the pathogenesis of the different inflammatory myopathies.Hum Pathol 1986;17: 704–721.

    Article  CAS  PubMed  Google Scholar 

  6. Ringel SP, Carry MR, Aquilera AJ, Starcevich JM. Quantitative histopathology of the inflammatory myopathies.Arch Neurol 1984;43: 1004–1009.

    Article  Google Scholar 

  7. Whitaker JN, Engel WK. Vascular deposits of immunoglobulin and complement in idiopathic inflammatory myopathy.New Engl J Med 1972;286: 333–338.

    Article  CAS  PubMed  Google Scholar 

  8. Engel AG, Arahata K. Monoclonal antibody analysis of mononuclear cells in myopathies. II: phenotypes of autoinvasive cells in polymyositis and inclusion body myositis.Ann Neurol 1984;16: 209–215.

    Article  CAS  PubMed  Google Scholar 

  9. Emslie-Smith AM, Arahata K, Engel A. Major histocompatibility complex class I antigen expression, immuno-localization of interferen subtypes, and T cell-mediated cytotoxicity in myopathies.Hum Pathol 1989;20: 224–231.

    Article  CAS  PubMed  Google Scholar 

  10. Karpati G, Pouliot Y, Carpenter S. Expression of immunoreactive major histocompatibility complex products in human skeletal muscles.Ann Neurol 1988;23: 64–72.

    Article  CAS  PubMed  Google Scholar 

  11. Plotz PH, Dalakas M, Leff RL. Current concepts in idiopathic inflammatory myopathies: Polymyositis, dermatomyositis and related disorders.Ann Intern Med 1989;111: 143–157.

    Article  CAS  PubMed  Google Scholar 

  12. Targoff IN. Immunological aspects of myositis.Curr Opin Rheumatol 1989;1: 432–442.

    Article  CAS  PubMed  Google Scholar 

  13. Bunn CC, Bernstein RM. Autoantibodies against tRNA sythetase and tRNA A1a coexist and are associated with myositis.J Exp Med 1998;163: 1281–1291.

    Article  Google Scholar 

  14. Love LA, Leff RL, Fraser DD. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups.Medicine 1991;70: 360–374.

    Article  CAS  PubMed  Google Scholar 

  15. Mathews MB, Bernstein RM. Myositis autoantibody inhibits histidyl tRNA synthetase: a model for autoimmunity.Nature 1983;304:177–179.

    Article  CAS  PubMed  Google Scholar 

  16. Targoff IN. Immune mechanisms of myositis.Curr Opin Rheumatol 1990;2: 882–888.

    Article  CAS  PubMed  Google Scholar 

  17. Arnett FC, Hirsch TJ, Bias WB, Nishikai M, Reichlin M. The Jo-1 antibody system in myositis: relationships to clinical features and HLA.J Rheumatol 1981;8: 925–930.

    CAS  PubMed  Google Scholar 

  18. Bernstein RMet al. Anti-Jo-1 antibody: a marker for myositis with interstitial lung disease.BMJ 1984;289: 151–152.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Hochberg MC, Feldman D, Stevens MB, Arnett FC, Reichlin M. Antibody to Jo-1 in polymyositis/ dermatomyositis: association with interstitial pulmonary disease.J Rheumatol 1984;11: 663–665.

    CAS  PubMed  Google Scholar 

  20. Airio A, Pukkala E, Isomaki H. Elevated cancer incidence in patients with dermatomyositis: a population based study.J Rheumatol 1995;22: 1300–1303.

    CAS  PubMed  Google Scholar 

  21. Chow Wet al. Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark.Cancer Causes Control 1995;6: 9–13.

    Article  CAS  PubMed  Google Scholar 

  22. Koh ETet al. Adult onset polymyositis/dermatomyositis: clinical and laboratory features and treatment response in 75 patients.Ann Rheumatol Dis 1993;52: 857–861.

    Article  CAS  Google Scholar 

  23. Sigureisson B, Lindelof B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis: a population-based study.New Engl J Med 1992;326: 363–367.

    Article  Google Scholar 

  24. Callen JP. Myositis and malignancy.Cur Opin Rheumatol 1994;6: 590–594.

    Article  CAS  Google Scholar 

  25. Zantos D, Zhang Y, Felson D. The overall and temporal association of cancer with polymyositis and dermatomyositis.J Rheumatol 1994;2: 1855–1859.

    Google Scholar 

  26. Barnes BE. Dermatomyositis and malignancy: a review of the literature.Ann Intern Med 1976;84: 68–76.

    Article  CAS  PubMed  Google Scholar 

  27. Sais G, Marcoval J, Juggla A, Curco N, Servitje O. Dermatomyositis and malignant melanoma, with complete regression of the primary lesion.Br. J Dermatol 1994;130: 796–797.

    Article  CAS  PubMed  Google Scholar 

  28. Scerri L, Zaki I, Allen BR, Golden P. Dermatomyositis associated with malignant melanoma— case report and review of the literature.Clin Exp Dermatol 1994;19: 523–525.

    Article  CAS  PubMed  Google Scholar 

  29. Shorr AF, Jacavone M, Seguin S, Jackson LW, Dennis GJ. Dermatomyositis and malignant melanoma.Am J Med Sci 1997;313: 249–251.

    CAS  PubMed  Google Scholar 

  30. Sunnenberg TD, Kitchens CS. Dermatomyositis associated with malignant melanoma.Cancer 1983;51: 2157–2158.

    Article  CAS  PubMed  Google Scholar 

  31. Isaacs J, Lindenmann J 1957 Classical article: Virus interference. 1. The Interferon. By A Isaacs and J Lindenmann.J Interferon Res 1987;7: 429–438.

    Article  CAS  PubMed  Google Scholar 

  32. Lengyl P. Biochemistry of interferons and their actions.Annu Rev Biochem 1982;51: 251–282.

    Article  Google Scholar 

  33. Pestka S, Langer J, Zoon KC, Samuel CE. Interferons and their actions.Annu Rev Biochem 1987;56: 727–777.

    Article  CAS  PubMed  Google Scholar 

  34. Greiner JWet al. Enhanced expression of surface tumor-associated antigens on Human breast and colon tumor cells after recombinant human leukocyte alpha-interferon treatment.Cancer Res 1984;44: 3208–3214.

    CAS  PubMed  Google Scholar 

  35. Greiner JW, Fisher PB, Pestka S, Schlom J. Differential effects of recombinant human leukocyte interferons on cell surface antigen expression.Cancer Res 1986;46: 4984–4990.

    CAS  PubMed  Google Scholar 

  36. Lindahl P, Leary R, Gresser I. Enhancement by interferon of the specific cytotoxicity of sensitized lymphocytes.Proc Nat Acad Sci USA 1972;69: 721–725.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Ortaldo JRet al. Effects of recombinant and hybrid recombinant human leukocyte interferons on cytotoxic activity of natural killer cells.J Biol Chem 1983;258: 1501–1505.

    Article  Google Scholar 

  38. Ortaldo JRet al. Effects of several species of human leukocyte interferon on cytotoxic activity of NK cells and monocytes.Int J Cancer 1983;31: 285–289.

    Article  CAS  PubMed  Google Scholar 

  39. Ronnblom LE, Alm GV, Oberg KE. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumor.Ann Int Med 1991;151: 178–183.

    Article  Google Scholar 

  40. Revel M, Chebath J. Interferon activated genes.Trends Biol Sci 1986;11: 166–170.

    Article  CAS  Google Scholar 

  41. Heremans H, Billiau A, Columbatti A, Hilger J, de Somer P. Interferon treatment of NZB mice: accelerated progression of autoimmune disease.Infect Immun 1978;21: 925–930.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Gresser I, Maury C, Tovey M. Progressive glomerulonephritis in mice treated with interferon preparations at birth.Nature 1976;263: 420–422.

    Article  CAS  PubMed  Google Scholar 

  43. Schattner A, Duggan D, Naperstek Y, Schwartz RS. Effects of alpha-interferon on the expression of a lupus idiotype in normal humans.Clin Immunol Immunopathaol 1986;38: 327–336.

    Article  CAS  Google Scholar 

  44. Bayraktar Y, Bayrakta M, Gurakar A, Hassanein T, Van Thiel D. A comparison of the prevalence of autoantibodies in individuals with chronic hepatitis C and those with autoimmune hepatitis: the role of interferon in the development of autoimmune disease.Hepato-gastroenterology 1997;44: 417–425.

    CAS  PubMed  Google Scholar 

  45. Chazerain P, Meyer O, Kahn MF. Rheumatoid arthritis-like disease after alpha-interferon therapy.Ann Intern Med 1992;116: 427.

    Article  CAS  PubMed  Google Scholar 

  46. Conlon KCet al. Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy.Cancer 1990;65: 2237–2242.

    Article  CAS  PubMed  Google Scholar 

  47. Gisslinger Het al. Thyroid autoimmunity and hypothyroidism during long-term treatment with recombinant interferon-alpha.Clin Exp Immunol 1992;90: 363–367.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Herman J, Gabriel F. Membranoproliferative glomerulonephritis in a patient with hairy-cell leukemia treated with alpha-II-interferon.New Engl J Med 1987;316: 112–113.

    Article  Google Scholar 

  49. McLaughlin Pet al. Immune thromboyctopenia following a-interferon therapy in patients with cancer.JAMA 1985;254: 1353–1354.

    Article  CAS  PubMed  Google Scholar 

  50. Reid TJ, Lombardo FA, Redmond J, Hammond SL, Coffey JA. Digital vasculitis associated with interferon therapy.Am J Med 1992;92: 702–703.

    Article  PubMed  Google Scholar 

  51. Wandle UBet al. Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders.Clin Immunol Immunopathol 1992;65: 70–74.

    Article  Google Scholar 

  52. Hooks JJet al. Immune interferon in the circulation of patients with autoimmune disease.New Eng J Med 1979;301: 5–8.

    Article  CAS  PubMed  Google Scholar 

  53. Preble OT, Black RJ, Friedman RM, Klippel JH, Vilcek J. Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon.Science 1982;216: 429–431.

    Article  CAS  PubMed  Google Scholar 

  54. Ytterberg SR, Schnitzer TJ. Serum interferon levels in patients with systemic lupus erythematosus.Arthritis Rheumatol 1982;25: 401–406.

    Article  CAS  Google Scholar 

  55. Schattner A. Lymphokines in autoimmunity— a critical review.Clin Immunol Immunopathol 1994;70: 177–189.

    Article  CAS  PubMed  Google Scholar 

  56. Hooks JJet al. Multiple interferons in the circulation of patients with systemic lupus erythematosus and vasculitis.Arthritis Rheumatol 1982;25: 396–400.

    Article  CAS  Google Scholar 

  57. Schattner A. The lupus activity criteria count.J Rheumatol 1985;12: 1203.

    CAS  PubMed  Google Scholar 

  58. Kim Tet al. Serum levels of interferons in patients with systemic lupus erythematosus.Clin Exp Immunol 1987;70: 562–569.

    CAS  PubMed  PubMed Central  Google Scholar 

  59. Kirkwood JMet al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684.J Clin Oncol 1996;14: 7–17.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Section of Medical Oncology, University of Wisconson, Madison, Wisconsin, USA

    LL Dietrich & MR Albertini

  2. Department of Internal Medicine Section of Rheumatology, University of Wisconson, Madison, Wisconsin, USA

    AJ Bridges

  3. K4/414 Clinical Science Center, 600 Highland Avenue, 53792, Madison, Wisconsin, USA

    MR Albertini

Authors
  1. LL Dietrich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. AJ Bridges
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. MR Albertini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to MR Albertini.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dietrich, L., Bridges, A. & Albertini, M. Dermatomyositis after interferon alpha treatment. Med Oncol 17, 64–69 (2000). https://doi.org/10.1007/BF02826219

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02826219

Keywords

Search

Navigation